Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
IRBESARTAN
Atenolol
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Hypertension grade 1 or 2
With at least two of the following criteria for the diagnosis of metabolic syndrome:
- Body mass index > or = 25 kg/m2 AND waist circumference > or = 100 cm.
- Dyslipidemia (triglycerides fasting serum levels > or = 200 mg/dL OR HDL serum levels < or = 40 mg/dL)
- Fasting serum glucose > or = 110 mg/dL but < 126 mg/dL
Exclusion Criteria:
- Known hypersensitivity to Irbesartan
- Hypertension grade 3
- History of clinical vascular events such as TIAs, stroke, peripheral arterial disease
- Coronary artery disease
- Renal insufficiency (creatinine serum levels > or = 1.2 mg/dL)
- Presence of clinical heart failure
- Asthma and COPD
- Valvular cardiopathy clinically relevant
- Current therapy with antioxidant drugs, statins
- Therapy with AIIRA for at least 3 months during the last semester
- Presence of any acute illness or major trauma in the last 8 weeks
- History of a chronic inflammatory disease such as rheumatoid arthritis, immune disorders or connective tissue disease.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Irbesartan Group
Atenolol Group
Arm Description
150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
Outcomes
Primary Outcome Measures
Endothelial function in vivo qualification: brachial artery flow mediated vasodilation (FMV%) determined by high resolution ultrasound.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00529750
Brief Title
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
Official Title
Comparative Trial of the Effects of Irbesartan vs Atenolol on the Endothelial Function of Hypertensive Patients With Metabolic Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
July 2002 (undefined)
Primary Completion Date
January 2005 (Actual)
Study Completion Date
January 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Sanofi
4. Oversight
5. Study Description
Brief Summary
Primary:
To evaluate the impact of irbesartan on endothelial function in hypertensive patients with metabolic syndrome.
Secondary:
To evaluate the oxidative stress status in patients with hypertension with metabolic syndrome.
To correlate the oxidative stress status with endothelial function in these patients.
To evaluate the effect of irbesartan on the oxidative stress stage in patients with metabolic syndrome and to correlate it with the effect on endothelial function .
To correlate the change in endothelial function and oxidative stress stage with the change of arterial pressure levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
108 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Irbesartan Group
Arm Type
Experimental
Arm Description
150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
Arm Title
Atenolol Group
Arm Type
Active Comparator
Arm Description
50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
Intervention Type
Drug
Intervention Name(s)
IRBESARTAN
Intervention Description
Tablets
Intervention Type
Drug
Intervention Name(s)
Atenolol
Intervention Description
Tablets
Primary Outcome Measure Information:
Title
Endothelial function in vivo qualification: brachial artery flow mediated vasodilation (FMV%) determined by high resolution ultrasound.
Time Frame
at baseline and at the end of the study-12th wk
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hypertension grade 1 or 2
With at least two of the following criteria for the diagnosis of metabolic syndrome:
Body mass index > or = 25 kg/m2 AND waist circumference > or = 100 cm.
Dyslipidemia (triglycerides fasting serum levels > or = 200 mg/dL OR HDL serum levels < or = 40 mg/dL)
Fasting serum glucose > or = 110 mg/dL but < 126 mg/dL
Exclusion Criteria:
Known hypersensitivity to Irbesartan
Hypertension grade 3
History of clinical vascular events such as TIAs, stroke, peripheral arterial disease
Coronary artery disease
Renal insufficiency (creatinine serum levels > or = 1.2 mg/dL)
Presence of clinical heart failure
Asthma and COPD
Valvular cardiopathy clinically relevant
Current therapy with antioxidant drugs, statins
Therapy with AIIRA for at least 3 months during the last semester
Presence of any acute illness or major trauma in the last 8 weeks
History of a chronic inflammatory disease such as rheumatoid arthritis, immune disorders or connective tissue disease.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan Carlos Gomez
Organizational Affiliation
Sanofi
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
We'll reach out to this number within 24 hrs